# Bovine Respiratory Disease Vaccine Selection: A Comparative Guide


## Key Takeaways

- Modified-live vaccines (MLV) generally induce broader cell-mediated and mucosal immunity, particularly beneficial for viral pathogens like BVDV where cell-mediated immunity aids in clearance and cross-protection. Killed vaccines offer safety for pregnant or stressed animals but typically require a primary series and booster for adequate protection.
- Intranasal MLV vaccines provide rapid local immunity (48-72 hours) by stimulating IgA and interferon responses in the upper respiratory tract, bypassing maternal antibody interference in young calves, while injectable MLV vaccines elicit systemic immunity (10-14 days onset) and are more suitable for older animals or feedlot arrivals.
- Revaccination strategy significantly impacts immune phenotype; consistent use of MLV products promotes a balanced adaptive response, whereas switching to an inactivated vaccine can skew responses toward a proinflammatory profile with enhanced neutrophil chemotaxis and higher serum neutralizing antibody titers.
- Bacterial vaccine efficacy, particularly for *Mannheimia hemolytica*, cannot be solely inferred from serotype matching; some attenuated live vaccines containing A1 antigen have demonstrated cross-serotype protection against A6 challenge, reducing clinical scores and lung lesions.
- Inconsistent reporting in BRD vaccine trials, where control groups are often not truly unvaccinated, complicates direct product-to-product efficacy comparisons; clinicians must scrutinize study methodologies to understand the actual comparisons being tested.
- Temperature-sensitive MLV components, such as for IBR, are designed to replicate in cooler upper respiratory tract temperatures but not core body temperature, reducing systemic spread and demonstrating no adverse effects on reproductive parameters in nulliparous heifers when administered according to label directions.

---

Bovine respiratory disease (BRD) remains the most economically significant infectious disease complex affecting beef cattle, particularly in post-weaning and feedlot phases. Vaccine selection is one component of a broader prevention program that includes nutrition, commingling strategy, and biosecurity. This article provides a comparative framework for selecting among available BRD vaccine products based on antigen composition, formulation type, route of administration, and timing relative to production events. It serves practicing veterinarians advising cow-calf operations, stocker enterprises, and feedlots, and addresses the practical question of how to match vaccine characteriztics to specific production system constraints.

The evidence base for BRD vaccine selection is complicated by inconsistent trial reporting. A systematic evaluation of randomized controlled trials in feedlot cattle found that most publications labeled control groups as "unvaccinated" even when all cattle received some respiratory vaccine at arrival, and most statistical comparisons failed to disclose the background vaccines administered to all animals. These reporting deficiencies obscure the true comparisons being tested and complicate direct product-to-product inference. Clinicians should therefore interpret comparative efficacy claims with attention to what the control group actually received.

## At a Glance

| Parameter | Decision Point | Clinical Consideration |
|---|---|---|
| Formulation type | Modified-live (MLV) vs. inactivated (killed) | MLV generally induces broader cell-mediated and mucosal responses, killed vaccines offer safety in certain pregnant or stressed cohorts |
| Antigen coverage | Viral (IBR, BVDV 1 and 2, PI-3, BRSV) vs. bacterial (Mannheimia, Pasteurella, Histophilus) | Match to the pathogens most prevalent in the source and destination populations |
| Route | Intranasal vs. parenteral | Intranasal provides rapid local immunity and bypasses maternal antibody interference, parenteral offers convenience and combination flexibility |
| Timing | Pre-weaning, at arrival, or revaccination | Preconditioning programs favor MLV priming, arrival protocols may require rapid-onset products |
| Revaccination strategy | Same product vs. switching formulation | Switching from MLV to inactivated at revaccination alters the immune phenotype and may skew responses toward a proinflammatory profile |
| Serotype coverage | Mannheimia hemolytica A1 vs. A6 | Some attenuated bacterial vaccines provide cross-serotype protection despite not containing A6 antigen |
| Production system | Cow-calf, stocker, feedlot | Risk period, handling opportunities, and labor constraints determine practical choices |

## Immunologic Basis for Vaccine Selection

The protective immune response against BRD pathogens involves both humoral and cell-mediated arms. Modified-live vaccines replicate within the host, engaging major histocompatibility complex class I presentation and generating cytotoxic T lymphocyte responses that inactivated products cannot reliably produce. This distinction matters most for viral pathogens such as bovine viral diarrhea virus (BVDV), where cell-mediated immunity contributes to clearance of infected cells and cross-protection between strains.

Transcriptomic analysis of sub-clinically infected cattle comparing MLV and killed BVDV vaccines found that MLV produced cross-protection that extended the adaptive immune response to BVDV beyond what killed vaccines achieved. Both formulations provided some protection over non-vaccinated controls, but the qualitative nature of the response differed. This differential immune activation has practical consequences for herds with persistent BVDV infection risk or where challenge pressure is high.

### Immune Phenotype and Revaccination

The choice of revaccination product after an initial MLV priming dose influences the resulting immune phenotype. In beef heifers given an MLV at 3 to 4 months of age, those receiving two additional MLV doses developed a balanced adaptive response with increases in IL-17, IL-21, and both IgG1 and IgG2 subclasses. Heifers switched to an inactivated product for revaccination showed enhanced neutrophil chemotaxis and greater serum-neutralizing antibody titers but a skewed proinflammatory profile. For operations prioritizing long-term immune homeostasis, maintaining the same MLV formulation through the booster schedule may be preferable. For operations seeking maximal neutralizing antibody before a high-risk period, the mixed protocol may offer an advantage despite its inflammatory skew.

## Attenuation Mechanisms and Product Characteriztics

Live attenuated vaccines differ in the molecular basis of their attenuation, which affects their safety profile and field behavior. Whole genome sequencing of a live attenuated bovine adenovirus type 7 vaccine strain used in a hexavalent BRD product identified a mutation in the minor capsid protein pVI that likely alters membrane-lytic function and a 19-base pair insertion in the inverted terminal repeat that may affect promoter activity. These specific genetic changes underlie the temperature-sensitive growth characteriztics that distinguish attenuated strains from their pathogenic progenitors. Understanding that attenuation is strain-specific instead of a generic property of "modified-live" products informs expectations about reversion risk and vaccine virus shedding.

Temperature-sensitive MLV components, particularly for infectious bovine rhinotracheitis (IBR), are designed to replicate at the cooler temperatures of the upper respiratory tract but not at core body temperature. This property reduces systemic spread and may influence safety in specific cohorts. A study comparing a temperature-sensitive MLV IBR component with a killed IBR component in nulliparous heifers found no differences in estrous cycle parameters, luteal tissue area, or anti-Müllerian hormone concentrations between groups, suggesting that neither formulation disrupts reproductive function when administered to previously vaccinated animals.

## Bacterial Vaccine Cross-Protection

Bacterial components of BRD vaccines present distinct selection challenges. Mannheimia hemolytica serotypes A1 and A6 account for most clinical isolates, yet many commercial vaccines contain only A1 antigen. A study of an attenuated live vaccine containing M. hemolytica A1 and Pasteurella multocida demonstrated protection against experimental challenge with M. hemolytica A6, with vaccinated calves showing reduced clinical scores, lower mortality, and significantly lower lung lesion scores compared with placebo controls. This cross-serotype protection indicates that vaccine efficacy cannot be inferred solely from serotype matching of the antigen content. Clinicians should evaluate challenge data for the serotypes prevalent in their region instead of assuming serotype-specific coverage is required.

## Study Design Considerations for Evidence Interpretation

When comparing BRD vaccine trials, the control group definition determines what the study actually demonstrates. Trials comparing a new vaccine against an established product answer a different question than trials comparing a vaccine against no respiratory vaccination. The reporting deficiencies documented in feedlot vaccine trials mean that published abstracts may misrepresent the comparison performed. Clinicians should examine methods sections for the full list of products administered to all animals, including those labeled as controls, before applying trial results to their own vaccine selection decisions.

## Route of Administration: Intranasal versus Injectable

Route selection changes the onset, duration, and anatomic character of the immune response. Intranasal modified-live vaccines deliver antigen directly to the nasal mucosa and upper respiratory tract, where they induce local IgA production and interferon-mediated innate responses within 48 to 72 hours. This makes them useful when calves face imminent commingling or transport and when the interval between vaccination and exposure is short. Injectable modified-live vaccines produce a more systemic response with strong serum neutralizing antibody and cell-mediated immunity, but they require 10 to 14 days to generate protective immunity in a naive animal. Killed injectable vaccines rely on adjuvants and require a primary series followed by a booster to reach protective titers.

The choice between intranasal and injectable products is influenced by the animal's age and maternal antibody status. Young calves with high levels of maternally derived antibody may not respond adequately to injectable modified-live vaccines because passively acquired antibody neutralizes the vaccine virus. Intranasal modified-live vaccines are less affected by maternal antibody because they replicate at the mucosal surface and stimulate local immunity before systemic interference becomes relevant. For preweaning vaccination programs in calves under four months of age, intranasal products are frequently the more reliable choice. In older calves and feedlot arrivals where systemic immunity is the goal, injectable products are appropriate.

The immune phenotype produced by revaccination depends on the sequence of products used. Heifers that received a modified-live vaccine at three to four months of age and then a modified-live booster at weaning and again 28 days later showed a balanced adaptive immune response with increases in IL-17, IL-21, and both IgG1 and IgG2 subclasses. Heifers that received the initial modified-live dose followed by two doses of an inactivated vaccine developed a more robust neutrophil chemotactic response and higher serum neutralizing titers, but with a skewed proinflammatory profile. These findings indicate that the choice of revaccination product alters the character of the immune response, also its magnitude. For operations where a balanced immune response is preferred, such as long-fed cattle facing multiple pathogen exposures, consistent use of modified-live products across the vaccination series may be preferable. Where enhanced humoral titers are the goal, such as short-fed cattle marketed within 90 days of arrival, the modified-live followed by killed sequence may be selected despite its proinflammatory bias.

## Production System Considerations

Beef production systems differ in the timing of vaccine administration, the duration of risk, and the pathogens most likely to be encountered. Cow-calf operations vaccinate calves during the preweaning period, often at branding and again at weaning. The primary goal is to establish immunity before commingling and transport to the feedlot. Feedlot operations vaccinate on arrival, when calves are already stressed and potentially incubating disease. Backgrounding operations may vaccinate multiple times over a 45 to 60 day period before cattle move to finishing facilities.

For cow-calf operations, the initial vaccination at branding should use products that overcome maternal antibody interference. Intranasal modified-live vaccines are well suited here. The weaning booster should switch to an injectable modified-live product to broaden systemic immunity before the calf leaves the ranch. This sequence provides both local and systemic coverage and is practical because calves are handled twice under controlled conditions.

Feedlot arrival vaccination faces different constraints. Cattle may be of unknown vaccination history, may be stressed from transport, and may already be incubating viral or bacterial infection. Modified-live injectable vaccines are generally preferred because they produce a more rapid and complete immune response than killed products in a single dose. However, the stress response associated with arrival can suppress the immune response to vaccination. Some operations delay vaccination for 7 to 14 days after arrival to allow cattle to recover from transport stress, while others vaccinate immediately to capture the earliest possible protection. The evidence base for this decision is limited by inconsistent reporting in feedlot vaccine trials. A review of published trials found that most studies labeled control groups as unvaccinated even when all cattle received some vaccine at arrival, and most statistical comparisons did not account for the respiratory vaccines given to all cattle. This makes it difficult to draw firm conclusions about the optimal timing of arrival vaccination relative to stress and disease challenge.

Bacterial vaccines are selected based on the pathogens most prevalent in the operation's history and the production phase. Mannheimia hemolytica is the most commonly isolated bacterial pathogen in feedlot respiratory disease, and serotypes A1 and A6 are the most frequently recovered. Many commercial vaccines are based on serotype A1, and there is evidence that an attenuated live vaccine containing M. hemolytica A1 can protect against challenge with serotype A6, reducing clinical scores, mortality, and lung lesion severity. This cross-serotype protection is relevant for feedlot operations where the circulating serotype may not match the vaccine strain. Histophilus somni and Pasteurella multocida vaccines are often combined with M. hemolytica antigens in multivalent products, and the choice of bacterial components should reflect the operation's diagnostic history.

## Comparative Table of Vaccine Types

| Vaccine Type | Route | Onset of Protection | Duration | Indications | Limitations |
|---|---|---|---|---|---|
| Modified-live viral | Injectable | 10 to 14 days | 6 to 12 months | Feedlot arrival, weaning boosters, cattle with unknown history | Interference from maternal antibody in young calves, requires cold chain, not for use in pregnant cattle unless labeled safe |
| Modified-live viral | Intranasal | 48 to 72 hours | 3 to 6 months | Preweaning calves, imminent commingling, maternal antibody interference | Local reactions possible, limited systemic immunity, may require repeat dosing |
| Killed viral | Injectable | 14 to 21 days after booster | 6 months | Pregnant cattle, initial vaccination in naive adults, operations preferring killed products | Requires two doses for primary series, slower onset, adjuvants may cause injection site reactions |
| Attenuated live bacterial | Injectable | 7 to 14 days | 3 to 6 months | Feedlot arrival, high-risk cattle, cross-serotype protection | Requires reconstitution, not for use in immunocompromised animals |
| Killed bacterial | Injectable | 14 to 21 days after booster | 4 to 6 months | Cow-calf preconditioning, low-risk feedlot cattle | Two-dose series required, limited cell-mediated response |

## Patient Status and Contraindications

Pregnancy status is a primary determinant of vaccine selection. Modified-live viral vaccines carry label restrictions against use in pregnant cattle unless the product is specifically labeled as safe for use in pregnant animals. The concern is fetal infection with vaccine virus, particularly bovine viral diarrhea virus and infectious bovine rhinotracheitis virus. Killed products are the standard choice for pregnant replacement heifers and cows when the vaccination history is unknown. Some modified-live products have been shown to be safe in pregnant cattle, and a study of a temperature-sensitive modified-live infectious bovine rhinotracheitis component found no effect on estrous cycle parameters, progesterone concentrations, luteal tissue area, or anti-Müllerian hormone concentrations in nulliparous heifers. However, product labels must be consulted for each specific vaccine, and the decision to use a modified-live product in pregnant cattle should be based on the labeled indication and the herd's risk profile.

Immunocompromised cattle, including those with persistent bovine viral diarrhea virus infection, should not receive modified-live vaccines because vaccine virus replication may be unchecked. Killed products are safer in these animals, although the immune response may be suboptimal. Cattle with concurrent disease or severe parasitism may not mount an adequate response to any vaccine, and vaccination should be deferred until the animal is stabilized.

## Documentation and Monitoring

Vaccination records should include the product name, serial number, route, dose, and the identity of each animal or group vaccinated. The date of administration and the expected onset of protective immunity should be recorded so that the interval between vaccination and exposure is known. For feedlot operations, the arrival vaccination protocol should be documented in the treatment records, and any deviation from the protocol should be noted with the reason for the deviation.

Monitoring the response to vaccination is indirect in beef cattle. Serologic testing is rarely performed on individual animals because of cost and the difficulty of interpreting titers in a population. Instead, operations monitor morbidity and mortality rates, the timing of respiratory disease outbreaks relative to vaccination, and the pathogens isolated from affected animals. A rise in respiratory disease cases within the expected window of vaccine onset may indicate that the vaccine was given too late relative to exposure, that the wrong antigenic coverage was selected, or that the product was mishandled. The [USDA APHIS animal health information](https://www.aphis.usda.gov/livestock-poultry-disease) resources provide guidance on disease reporting and surveillance that can support these monitoring efforts.

## Recognized Complications and Early Detection

Vaccine-associated adverse events in cattle are uncommon but predictable. The most frequently observed complication is anaphylactoid reaction, typically occurring within minutes to hours after administration of products containing inactivated antigens or adjuvants. Early signs include dyspnoea, salivation, muscle fasciculation, and recumbency. Detection depends on observing cattle for 30 to 60 minutes after vaccination and instructing handlers to report any animal found down or distressed within 12 hours.

Injection-site abscesses and local swellings arise from contaminated needles, improper anatomic placement, or repeated use of the same site. These are detected during routine processing or at recheck examination. Deep intramuscular injections in the neck that track along fascial planes can produce lameness or torticollis, findings that should prompt ultrasound examination to distinguish abscess from hematoma or vaccine granuloma.

Modified-live viral vaccines carry a recognized risk of fetal infection when administered to pregnant animals, particularly those without prior vaccination history. Early detection of this failure mode is retrospective, appearing as abortion storms or congenitally abnormal calves. The discriminating check is a thorough breeding-history review before administration, not post-hoc diagnostics.

Temperature-sensitive modified-live infectious bovine rhinotracheitis components have been evaluated for effects on ovarian function. One study in nulliparous heifers found no impact on oestrous cycle parameters or anti-Müllerian hormone concentrations following vaccination with either temperature-sensitive modified-live or killed IBR components, supporting their use in breeding-age females when label directions are followed.

## Common Errors and Corrective Actions

Less experienced clinicians frequently misread vaccine labels regarding route and booster intervals. Intranasal products administered by injection, or injectable products given intranasally, produce either no immunity or unexpected adverse reactions. The corrective action is a two-person verification protocol during processing: one person reads the label aloud, the second confirms the route and dose before the syringe is filled.

A second recurring error is the assumption that all cattle in a pen received the same vaccine. Processing records that list only the product name, without lot number, route, and individual animal identification, cannot support outbreak investigations. The corrective action is a standardized record form that captures lot numbers and maps them to pen or tag numbers.

A third error involves revaccination protocols. One study in beef heifers demonstrated that switching from modified-live to inactivated vaccine at revaccination produced a different immune phenotype than continuing with modified-live, including enhanced neutrophil chemotaxis and a skewed proinflammatory response. Clinicians who switch products without documenting the rationale lose the ability to interpret subsequent diagnostic titres or outbreak patterns.

## Limitations of Current Evidence

The published literature on BRD vaccine efficacy contains substantial reporting deficiencies. An evaluation of randomised controlled trials in feedlot cattle found that 56% of publications labelled control groups as unvaccinated when all cattle in the trial actually received vaccine at arrival, and 58% of trials reported statistical comparisons without mentioning the respiratory vaccines given to all cattle. This means that apparent vaccine effects may actually reflect differences in timing, route, or product formulation instead of vaccination versus no vaccination.

Cross-protection between bacterial serotypes remains incompletely characterized. One study demonstrated that an attenuated live vaccine containing Mannheimia hemolytica A1 and Pasteurella multocida reduced clinical scores, mortality, and lung lesions after challenge with M. hemolytica A6, but the authors noted the challenge was more severe than expected and called for further work. Whether this cross-protection extends to other serotypes or field strains is unknown.

The molecular basis of attenuation for some modified-live vaccines is only now being described. Whole genome sequencing of a bovine adenovirus type 7 vaccine strain identified specific mutations and insertions that may underlie its temperature-sensitive growth and attenuation, but the authors stated that further mutational and functional analyzes are required. Clinicians should recognize that product labels cannot fully describe the immunologic consequences of attenuation.

Expert opinion still differs on whether killed viral vaccines provide adequate priming for subsequent modified-live boosters. Transcriptomic work in Nellore-Angus cattle suggests modified-live vaccines produce broader cross-protection against BVDV than killed vaccines, but the clinical significance of these gene expression differences remains uncertain. In practice, some consultants recommend modified-live priming followed by modified-live boosters, while others accept killed priming when handling or storage constraints preclude modified-live use.

## Referral, Consultation, and Reporting

Referral to a veterinary diagnostic laboratory is warranted when vaccine-associated adverse events cluster in time or space, when abortion rates exceed historical baselines within one incubation period of vaccination, or when suspected vaccine failure coincides with a new viral isolate. Laboratory involvement should include virus isolation or PCR on nasal swabs and lung tissue, paired serology, and histopathology on affected animals.

Specialist consultation with a veterinary immunologist or feedlot production medicine specialist is appropriate when a herd experiences recurrent BRD despite apparently appropriate vaccination, or when revaccination protocols produce unexpected clinical outcomes. The consultant can review processing records, vaccine handling logs, and diagnostic data to identify system-level failures.

Regulatory reporting obligations vary by jurisdiction. The [USDA APHIS animal health information](https://www.aphis.usda.gov/livestock-poultry-disease) portal describes reportable disease requirements in the United States, while the [WOAH terrestrial animal health standards](https://www.woah.org/en/what-we-do/standards/codes-and-manuals/terrestrial-code-online-access/) define international notification obligations. Suspected vaccine-associated adverse events should also be reported to the manufacturer and to the relevant national pharmacovigilance program, as these reports drive label revisions and withdrawal decisions.

| Observation | Likely cause | Discriminating check |
|---|---|---|
| Acute collapse within 1 hour of vaccination | Anaphylactoid reaction to adjuvant or antigen | Time from injection, response to epinephrine, absence of injection-site swelling |
| Neck swelling with lameness 3 to 7 days after processing | Injection-site abscess or granuloma | Ultrasound to identify fluid pocket versus solid mass, culture if abscess drained |
| Abortion storm 2 to 8 weeks after modified-live vaccination | Fetal infection from modified-live virus in pregnant animal | Breeding records, fetal PCR, vaccine lot and route verification |
| Apparent vaccine failure with respiratory disease 2 to 4 weeks post-arrival | Incomplete priming, immunosuppression, or mismatched serotype | Paired serology, viral and bacterial PCR, review of processing records for missed boosters |
| Titres do not rise after booster | Prior vaccination masked by maternal antibody, or product mishandled | Check cold chain records, confirm booster interval, consider revaccination with different product class |

## Frequently Asked Questions

### How Do I Choose Between Modified-Live and Killed Vaccines When Cost Is the Primary Constraint?

When budget drives the decision, killed vaccines often appear cheaper per dose, but the comparison must include the full protocol. Killed products typically require two doses for primary immunization, whereas many modified-live vaccines establish protection with a single dose followed by annual boosters. Labor, handling time, and the risk of incomplete compliance with a two-dose schedule add hidden costs. The [MSD Veterinary Manual](https://www.msdvetmanual.com/) provides general guidance on vaccine selection principles, while [USDA APHIS animal health information](https://www.aphis.usda.gov/livestock-poultry-disease) outlines disease control priorities that may influence product choice. For high-risk calves entering the feedlot, the superior cell-mediated response of modified-live vaccines may justify the higher upfront cost despite the apparent price advantage of killed products.

### What Should I Do When Intranasal Vaccines Are Unavailable or the Restraint System Cannot Support Them?

When intranasal administration is not feasible, injectable modified-live vaccines remain the standard alternative for viral components. The temperature-sensitive modified-live infectious bovine rhinotracheitis component has been evaluated for safety in heifers, with no adverse effects on oestrous cycle parameters or ovarian reserve, supporting its use in breeding-age females where injectable products are preferred. For bacterial coverage, an attenuated live Mannheimia hemolytica vaccine administered parenterally has demonstrated cross-serotype protection against challenge with serotype A6, making it a viable option when intranasal bacterial products are unavailable. If the restraint system cannot safely accommodate intranasal delivery, prioritize injectable viral vaccines and adjust the bacterial component based on the predominant pathogens in the local population.

### How Does Vaccine Selection Differ for Dairy Calves Compared with Beef Calves?

Dairy calves face different risk windows and management constraints than beef calves. Dairy operations typically vaccinate earlier, often between two and four months of age, when maternal antibody interference is a greater concern. Modified-live vaccines may be less effective in the presence of high maternal antibody titres, whereas killed products can be administered earlier but require boosters. The [FAO animal production and health guidance](https://www.fao.org/animal-production/en/) emphasizes that production system differences, including housing density and weaning age, should inform disease control strategies. Dairy calves housed in groups face sustained pathogen pressure, favouring intranasal products that stimulate local immunity rapidly. Beef calves undergoing preconditioning before weaning have a defined vaccination window that allows timing of the primary series and booster to optimize immune response before transport.

### What Records Should I Maintain for BRD Vaccination Programs to Support Herd-Level Decisions?

Record keeping should capture vaccine type, route, lot number, administration date, and the individual animal or group identifier. For feedlot and preconditioning programs, also record the timing relative to arrival, weaning, and any concurrent treatments. The [AVMA practice resources](https://www.avma.org/resources-tools) provide frameworks for medical record documentation that support both clinical decision-making and liability protection. Accurate records allow retrospective analysis of BRD morbidity and mortality by vaccine protocol, which is essential because [incomplete reporting in randomised controlled trials of BRD vaccines](https://pubmed.ncbi.nlm.nih.gov/40179968/) has shown that published comparisons often fail to disclose all vaccines administered to control groups. Without complete records, you cannot determine whether a perceived vaccine failure reflects product efficacy or protocol drift.

### How Should I Explain Vaccine Selection to a Producer Who Wants a Single Product for All Age Groups?

A single product for all age groups is rarely optimal because immune status, risk level, and production stage differ across cohorts. Explain that [immune phenotype is differentially affected by changing the type of vaccine administered at revaccination](https://pubmed.ncbi.nlm.nih.gov/37138923/), meaning the protocol matters as much as the product. A calfhood modified-live prime followed by a killed booster produces a different immune profile than three doses of modified-live vaccine. Frame the recommendation around risk: calves entering a high-risk feedlot need rapid, broad protection, while breeding stock requires safety for reproductive function. Offer a two-product protocol, one for calves and one for adults, and explain the economic rationale in terms of reduced treatment costs and mortality instead of vaccine price alone.

### What Is the Role of Whole-Genome Sequencing in Vaccine Selection or Quality Assurance?

Whole-genome sequencing is not a routine clinical tool for vaccine selection, but it informs product understanding at the regulatory and manufacturing level. [Genomic analysis of a live attenuated bovine adenovirus type 7 vaccine strain](https://doi.org/10.21203/rs.3.rs-276827/v1) identified specific mutations and insertions associated with attenuation, providing biomarkers that manufacturers can use to verify vaccine consistency. For the practitioner, this matters because it supports confidence in the stability and safety of modified-live products across lots. If a producer questions vaccine safety or you observe unexpected reactions, knowing that attenuation mechanisms are molecularly characterized allows you to distinguish vaccine-related issues from concurrent disease. This information is most useful when investigating suspected vaccine failures or when selecting products for naive herds where attenuation safety is a primary concern.

## Related Clinical & Scientific Guides

* [Rumen Health Assessment in Dairy Cows: Clinical and Subclinical Indicators](/knowledge/veterinary-medicine/food-animal-medicine/rumen-health-assessment-dairy-cows-clinical-subclinical-indicators)
* [Mastitis Control Programs in Dairy Herds: Monitoring and Prevention](/knowledge/veterinary-medicine/food-animal-medicine/mastitis-control-programs-dairy-herds-monitoring-prevention)
* [Swine Nutrition and Health: Feed-Related Disease Diagnosis](/knowledge/veterinary-medicine/food-animal-medicine/swine-nutrition-health-feed-related-disease-diagnosis)


## References and Further Reading

- [Whole genome sequencing of live attenuated bovine adenovirus type 7 vaccine strain TS-GT reveals biomarkers for virulence attenuation](https://doi.org/10.21203/rs.3.rs-276827/v1). 2021.
- [Incomplete reporting in randomized controlled trials of bovine respiratory disease vaccines in feedlot cattle.](https://pubmed.ncbi.nlm.nih.gov/40179968/). 2025.
- [Transcriptomic analysis among sub-clinically ill cattle following Bovine Respiratory Disease vaccine protocol and challenge with Bovine Viral Diarrhea Virus](https://doi.org/10.21203/rs.2.16902/v1). 2019.
- [Cross protection of a Mannheimia hemolytica A1 Lkt-/Pasteurella multocida ΔhyaE bovine respiratory disease vaccine against experimental challenge with Mannheimia hemolytica A6 in calves.](https://pubmed.ncbi.nlm.nih.gov/22306859/). 2012.
- [Immune phenotype is differentially affected by changing the type of bovine respiratory disease vaccine administered at revaccination in beef heifers.](https://pubmed.ncbi.nlm.nih.gov/37138923/). 2023.
- [Influence of a bovine respiratory disease vaccine with a temperature-sensitive modified live or killed infectious bovine rhinotracheitis component on oestrous cycle parameters and anti-Müllerian hormone concentration in nulliparous heifers.](https://pubmed.ncbi.nlm.nih.gov/31444980/). 2019.
- [USDA APHIS Animal Health Information](https://www.aphis.usda.gov/livestock-poultry-disease). USDA APHIS.
- [FAO Animal Production and Health](https://www.fao.org/animal-production/en/). FAO.
- [MSD Veterinary Manual, Professional Edition](https://www.msdvetmanual.com/). MSD Veterinary Manual.

## Related Articles

- [Bovine Respiratory Disease Prevention: Vaccination and Management Strategies](/knowledge/veterinary-medicine/food-animal-medicine/bovine-respiratory-disease-prevention-vaccination-management-strategies)
- [Differential Diagnosis of Acute Bovine Respiratory Disease in Feedlot Cattle](/knowledge/veterinary-medicine/food-animal-medicine/differential-diagnosis-acute-bovine-respiratory-disease-feedlot)
- [Diagnostic Approach to Respiratory Disease in Sheep and Goats](/knowledge/veterinary-medicine/food-animal-medicine/diagnostic-approach-respiratory-disease-sheep-goats)
- [Calf Health Scoring Chart: Application for Respiratory Disease Detection](/knowledge/veterinary-medicine/food-animal-medicine/calf-health-scoring-chart-application)
- [Swine Respiratory Disease Complex: Diagnostic Differentiation and Control](/knowledge/veterinary-medicine/food-animal-medicine/swine-respiratory-disease-complex-diagnostic-differentiation-control)

> This article is educational professional reference material for veterinary audiences. It is not a substitute for veterinary diagnosis, individual clinical judgment, current product labeling, or applicable regulatory requirements.